Lee's Pharmaceutical Holdings Limited (HK:0950)
:0950
Want to see HK:0950 full AI Analyst Report?
0950 Stock Chart & Stats
HK$1.55
-HK$0.01(-0.76%)
At close: 4:00 PM EST
HK$1.55
-HK$0.01(-0.76%)
Day’s Range― - ―
52-Week RangeHK$1.11 - HK$2.70
Previous CloseN/A
Volume7.00K
Average Volume (3M)5.40M
Market Cap
HK$677.16M
Enterprise ValueHK$619.87M
Total Cash (Recent Filing)HK$303.58M
Total Debt (Recent Filing)HK$243.63M
Price to Earnings (P/E)9.0
Beta0.65
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.92%
Share Statistics
EPS (TTM)0.04
Shares Outstanding588,835,300
10 Day Avg. Volume4,101,801
30 Day Avg. Volume5,400,283
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.44
Price to Sales (P/S)0.62
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and rising equity give the company financial resilience. Conservative debt-to-equity (~0.08–0.15) and an expanding capital base reduce refinancing and liquidity risk, enabling steady funding of R&D, licensing deals and commercial operations over the medium term.
Improving Operating Cash FlowImproved operating cash flow (332.9m in 2025 vs 242.0m in 2024) shows the core business is converting sales into cash more effectively. Sustained OCF supports working capital, product launches and milestone spending, lowering near-term dependency on external financing.
Diversified Pharma Commercial ModelThe business blends commercialization, in-licensing and manufacturing with multiple revenue streams (product sales, licensing fees, milestones, services). This diversified model provides revenue optionality, partner-funded R&D and scalable commercial leverage in the large China prescription market.
Bears Say
Volatile Revenue TrendsTop-line volatility — a 33% rebound in 2024 followed by a 3% decline in 2025 — indicates inconsistent product demand or lumpy milestone recognition. Such swings complicate forecasting, resource allocation and stable growth planning over the next several months.
Margin CompressionMargins narrowed meaningfully in 2025 (gross ~51% vs ~54%; operating ~4% vs ~8%), reducing earnings leverage. Persistent pricing, cost or product-mix pressures would constrain profitability and free cash generation unless management secures higher-margin products or sustainable cost improvements.
Weak/Volatile Free Cash FlowFree cash flow volatility and a sharp decline in 2025 (101.3m) point to high reinvestment needs or working-capital swings. Weak FCF limits the firm's ability to self-fund growth, pay consistent dividends or absorb shocks without resorting to external financing.
Lee's Pharmaceutical Holdings Limited News
0950 FAQ
What was Lee's Pharmaceutical Holdings Limited’s price range in the past 12 months?
Lee's Pharmaceutical Holdings Limited lowest stock price was HK$1.11 and its highest was HK$2.70 in the past 12 months.
What is Lee's Pharmaceutical Holdings Limited’s market cap?
Lee's Pharmaceutical Holdings Limited’s market cap is HK$677.16M.
When is Lee's Pharmaceutical Holdings Limited’s upcoming earnings report date?
Lee's Pharmaceutical Holdings Limited’s upcoming earnings report date is Sep 02, 2026 which is in 127 days.
How were Lee's Pharmaceutical Holdings Limited’s earnings last quarter?
Lee's Pharmaceutical Holdings Limited released its earnings results on Mar 30, 2026. The company reported HK$0.042 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.042.
Is Lee's Pharmaceutical Holdings Limited overvalued?
According to Wall Street analysts Lee's Pharmaceutical Holdings Limited’s price is currently Overvalued.
Does Lee's Pharmaceutical Holdings Limited pay dividends?
Lee's Pharmaceutical Holdings Limited pays a Quarterly dividend of HK$0.022 which represents an annual dividend yield of 2.92%. See more information on Lee's Pharmaceutical Holdings Limited dividends here
What is Lee's Pharmaceutical Holdings Limited’s EPS estimate?
Lee's Pharmaceutical Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lee's Pharmaceutical Holdings Limited have?
Lee's Pharmaceutical Holdings Limited has 588,835,300 shares outstanding.
What happened to Lee's Pharmaceutical Holdings Limited’s price movement after its last earnings report?
Lee's Pharmaceutical Holdings Limited reported an EPS of HK$0.042 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.515%.
Which hedge fund is a major shareholder of Lee's Pharmaceutical Holdings Limited?
Currently, no hedge funds are holding shares in HK:0950
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lee's Pharmaceutical Holdings Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.67%
12-Months-Change
Fundamentals
Return on Equity
5.66%
Trailing 12-Months
Asset Growth
32.32%
Trailing 12-Months
Company Description
Lee's Pharmaceutical Holdings Limited
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Aloxi and Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renaltransplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution to treat primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
Technical Analysis
Sihuan Pharmaceutical Holdings Group
―
―
Dawnrays Pharmaceutical Holdings Ltd.
―
China Shineway Pharmaceutical Group Limited
―
Shandong Xinhua Pharmaceutical Company Limited Class H
―
Options Prices
Currently, No data available
---